AMRI Increases HCQ Production in U.S.

Contract research, development and manufacturing organization, AMRI, said in the immediate and near term, it is increasing production of hydroxychloroquine sulfate active pharmaceutical ingredient (API) at its Rensselaer, NY, manufacturing facility to meet the rise in demand resulting from potential effectiveness of the product in treating COVID-19 symptoms. AMRI’s active Type II DMF for hydroxychloroquine sulfate (HCQ) is available to support increased need. The FDA authorized emergency use of HCQ to treat some hospitalized patients with COVID-191.

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.